PMID- 24382338
OWN - NLM
STAT- MEDLINE
DCOM- 20140825
LR  - 20211021
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 13
DP  - 2014 Jan 2
TI  - Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin 
      therapy for the treatment of patients with mixed dyslipidemia: an 8-week, 
      multicenter, double-blind, randomized, placebo-controlled study.
PG  - 1
LID - 10.1186/1476-511X-13-1 [doi]
AB  - BACKGROUND: Patients with mixed hyperlipidemia usually are in need of combination 
      therapy to achieve low-density lipoprotein cholesterol (LDL-C) and triglyceride 
      (TG) target values for reduction of cardiovascular risk. This study investigated 
      the efficacy and safety of adding a new hypolipidemic agent, coenzyme A (CoA) to 
      stable statin therapy in patients with mixed hyperlipidemia. METHODS: In this 
      multi-center, 8-week, double-blind study, adults who had received >/=8 weeks of 
      stable statin therapy and had hypertriglyceridemia (TG level at 2.3-6.5 mmol/L) 
      were randomized to receive CoA 400 U/d or placebo plus stable dosage of statin. 
      Efficacy was assessed by the changes in the levels and patterns of lipoproteins. 
      Tolerability was assessed by the incidence and severity of adverse events (AEs). 
      RESULTS: A total of 304 patients with mixed hyperlipidemia were randomized to 
      receive CoA 400 U/d plus statin or placebo plus statin (n = 152, each group). 
      After treatment for 8 weeks, the mean percent change in TG was significantly 
      greater with CoA plus statin compared with placebo plus statin (-25.9% vs -4.9%, 
      respectively; p = 0.0003). CoA plus statin was associated with significant 
      reductions in TC (-9.1% vs -3.1%; p = 0.0033), LDL-C (-9.9% vs 0.1%; p = 0.003), 
      and non- high-density lipoprotein cholesterol (-13.5% vs -5.7%; p = 0.0039). 
      There was no significant difference in the frequency of AEs between groups. No 
      serious AEs were considered treatment related. CONCLUSIONS: In these adult 
      patients with persistent hypertriglyceridemia, CoA plus statin therapy improved 
      TG and other lipoprotein parameters to a greater extent than statin alone and has 
      no obviously adverse effect. TRIAL REGISTRATION: Current Controlled Trials 
      ClinicalTrials.gov ID NCT01928342.
FAU - Lai, Jiangtao
AU  - Lai J
FAU - Wu, Bifeng
AU  - Wu B
FAU - Xuan, Tianming
AU  - Xuan T
AD  - Department of Cardiology, First Affiliated Hospital, College of Medicine, 
      Zhejiang University, 79# Qingchun Road, 310003 Hangzhou, China. 
      xuantianming2012@gmail.com.
FAU - Liu, Zhong
AU  - Liu Z
FAU - Chen, Junzhu
AU  - Chen J
LA  - eng
SI  - ClinicalTrials.gov/NCT01928342
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140102
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Triglycerides)
RN  - SAA04E81UX (Coenzyme A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Coenzyme A/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Dyslipidemias/*drug therapy
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Triglycerides/blood
PMC - PMC3881496
EDAT- 2014/01/03 06:00
MHDA- 2014/08/26 06:00
PMCR- 2014/01/02
CRDT- 2014/01/03 06:00
PHST- 2013/11/12 00:00 [received]
PHST- 2013/12/28 00:00 [accepted]
PHST- 2014/01/03 06:00 [entrez]
PHST- 2014/01/03 06:00 [pubmed]
PHST- 2014/08/26 06:00 [medline]
PHST- 2014/01/02 00:00 [pmc-release]
AID - 1476-511X-13-1 [pii]
AID - 10.1186/1476-511X-13-1 [doi]
PST - epublish
SO  - Lipids Health Dis. 2014 Jan 2;13:1. doi: 10.1186/1476-511X-13-1.